Form 10-Q - Quarterly report [Sections 13 or 15(d)]

S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Merus NV (NASDAQ:MRUS)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Merus NV Charts.

Merus NV (NASDAQ:MRUS)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Merus NV Charts.

Merus NV News

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
Sunday 12 January 2025 (2 days ago) • GlobeNewswire Inc.

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Monday 16 December 2024 (4 weeks ago) • Edgar (US Regulatory)

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
Monday 16 December 2024 (4 weeks ago) • GlobeNewswire Inc.

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
Saturday 7 December 2024 (1 month ago) • GlobeNewswire Inc.

Form 8-K - Current report
Thursday 5 December 2024 (1 month ago) • Edgar (US Regulatory)

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
Wednesday 4 December 2024 (1 month ago) • GlobeNewswire Inc.

Form 8-K - Current report
Monday 2 December 2024 (1 month ago) • Edgar (US Regulatory)

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer
Monday 2 December 2024 (1 month ago) • GlobeNewswire Inc.

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
Sunday 1 December 2024 (1 month ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 5 November 2024 (2 months ago) • Edgar (US Regulatory)

Merus Receives FDA extension of PDUFA for zenocutuzumab
Tuesday 5 November 2024 (2 months ago) • GlobeNewswire Inc.

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
Thursday 31 October 2024 (2 months ago) • GlobeNewswire Inc.

More Merus NV News Articles

Sustainable Green Team (PK)

AMC Entertainment

Digital Brand Media and ... (PK)

Good Vibrations Shoes (PK)

Moon Equity (PK)

FuelCell Energy

Tonix Pharmaceuticals

Fannie Mae (QB)

Therapeutic Solutions (PK)

KULR Technology

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions